Author(s): Carolina Lazzarino, Marcelo Iastrebner, Jacqueline Gonzalez, et al. Abstract: PS1259 Session topic: 10. Myelodysplastic syndromes – Clinical Background: Hypomethylating agents (HMA) are the first line option for high-risk patient and lower-risk patient with transfusion dependence, or, during the follow-up according to worsening clinical features. Thrombocytopenia is a frequent finding in myelodysplastic syndromes...
Pro zobrazení tohoto obsahu je třeba být přihlášen.